Smoking-induced risk of future cardiovascular disease is partly mediated by cadmium in tobacco: Malmö Diet and Cancer Cohort Study.


Journal

Environmental health : a global access science source
ISSN: 1476-069X
Titre abrégé: Environ Health
Pays: England
ID NLM: 101147645

Informations de publication

Date de publication:
14 06 2019
Historique:
received: 28 03 2019
accepted: 31 05 2019
entrez: 16 6 2019
pubmed: 16 6 2019
medline: 17 3 2020
Statut: epublish

Résumé

Smoking is a strong risk factor for cardiovascular disease (CVD) and causes exposure to cadmium, which is a pro-atherosclerotic metal. Cadmium exposure has also been shown to increase the risk of CVD, even after adjustment for smoking. Our hypothesis was that part of the risk of CVD in smokers may be mediated by cadmium exposure from tobacco smoke. We examined this hypothesis in a mediation analysis, trying to assess how much of the smoking-induced CVD risk could be explained via cadmium. We used prospective data on CVD (incidence and mortality) in a Swedish population-based cohort of 4304 middle-aged men and women (the Malmö Diet and Cancer Study). Blood cadmium was analyzed in base-line samples from 1991, and clinical events were followed up for 16-19 years based on registry data. Mediation analysis was conducted to evaluate the indirect effect (via cadmium) of smoking on CVD. Survival was analyzed by the accelerated failure time (AFT) model and the Aalen additive hazard model. The mean blood cadmium level in the study population was 0.43 μg/L (median 0.24 μg/L) and increased with recent and current smoking. As expected, shorter survival time (AFT model) and higher incidence rate (Aalen model) were found in current smokers for all CVD outcomes and this effect seemed to be partly mediated by cadmium. For the sum of acute myocardial infarction, bypass grafts and percutaneous coronary intervention, and death in ischemic heart disease, about half of the increased risk of such events in current smokers was mediated via cadmium, with similar results for the AFT and Aalen models. Cadmium plays an important role in smoking-induced CVDs. This provides evidence for mechanisms and is of importance for both individuals and policy makers.

Sections du résumé

BACKGROUND
Smoking is a strong risk factor for cardiovascular disease (CVD) and causes exposure to cadmium, which is a pro-atherosclerotic metal. Cadmium exposure has also been shown to increase the risk of CVD, even after adjustment for smoking. Our hypothesis was that part of the risk of CVD in smokers may be mediated by cadmium exposure from tobacco smoke. We examined this hypothesis in a mediation analysis, trying to assess how much of the smoking-induced CVD risk could be explained via cadmium.
METHODS
We used prospective data on CVD (incidence and mortality) in a Swedish population-based cohort of 4304 middle-aged men and women (the Malmö Diet and Cancer Study). Blood cadmium was analyzed in base-line samples from 1991, and clinical events were followed up for 16-19 years based on registry data. Mediation analysis was conducted to evaluate the indirect effect (via cadmium) of smoking on CVD. Survival was analyzed by the accelerated failure time (AFT) model and the Aalen additive hazard model.
RESULTS
The mean blood cadmium level in the study population was 0.43 μg/L (median 0.24 μg/L) and increased with recent and current smoking. As expected, shorter survival time (AFT model) and higher incidence rate (Aalen model) were found in current smokers for all CVD outcomes and this effect seemed to be partly mediated by cadmium. For the sum of acute myocardial infarction, bypass grafts and percutaneous coronary intervention, and death in ischemic heart disease, about half of the increased risk of such events in current smokers was mediated via cadmium, with similar results for the AFT and Aalen models.
CONCLUSIONS
Cadmium plays an important role in smoking-induced CVDs. This provides evidence for mechanisms and is of importance for both individuals and policy makers.

Identifiants

pubmed: 31200698
doi: 10.1186/s12940-019-0495-1
pii: 10.1186/s12940-019-0495-1
pmc: PMC6570857
doi:

Substances chimiques

Cadmium 00BH33GNGH

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

56

Subventions

Organisme : Vetenskapsrådet
ID : 2014-2265
Pays : International
Organisme : Forskningsrådet om Hälsa, Arbetsliv och Välfärd
ID : 2014-0171
Pays : International
Organisme : Sahlgrenska Universitetssjukhuset
ID : ALF 74580
Pays : International
Organisme : Hjärt-Lungfonden
ID : 2015-0469
Pays : International

Références

Environ Res. 2015 Jan;136:67-74
pubmed: 25460622
Epidemiology. 2013 May;24(3):421-9
pubmed: 23514838
Epidemiology. 2012 Jul;23(4):551-60
pubmed: 22526092
Epidemiology. 2015 Mar;26(2):e23-4
pubmed: 25643116
JAMA. 1995 Jul 12;274(2):155-60
pubmed: 7596004
Circ J. 2011;75(10):2491-5
pubmed: 21799275
Expert Rev Cardiovasc Ther. 2010 Jul;8(7):917-32
pubmed: 20602553
Am J Epidemiol. 2018 Apr 1;187(4):806-816
pubmed: 29020130
Eur J Epidemiol. 2013 Feb;28(2):113-7
pubmed: 23371044
Environ Res. 2018 Apr;162:240-260
pubmed: 29358116
Circulation. 1997 Nov 4;96(9):3243-7
pubmed: 9386200
Front Psychol. 2016 Mar 30;7:423
pubmed: 27065906
Heart Dis Stroke. 1992 Jul-Aug;1(4):173-5
pubmed: 1344104
Epidemiology. 2011 Jul;22(4):575-81
pubmed: 21552129
Atherosclerosis. 2016 Jun;249:209-14
pubmed: 27156912
BMJ Open. 2015 Jul 16;5(7):e008218
pubmed: 26185180
Tob Control. 2003 Dec;12(4):424-30
pubmed: 14660781
Environ Int. 2018 Dec;121(Pt 1):683-694
pubmed: 30316184
Circulation. 2006 May 16;113(19):2320-8
pubmed: 16651471
J Cardiovasc Pharmacol Ther. 2013 Nov;18(6):550-4
pubmed: 24038014
Int J Occup Med Environ Health. 2013 Mar;26(1):58-72
pubmed: 23526195
J Hypertens. 2013 Aug;31(8):1517-26
pubmed: 23743805
J Anal Toxicol. 2014 May;38(4):204-11
pubmed: 24535337
JAMA. 1993 Jan 13;269(2):232-6
pubmed: 8417241
J Intern Med. 1993 Jan;233(1):45-51
pubmed: 8429286
Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1392-8
pubmed: 19556524
Epidemiology. 2011 Jul;22(4):582-5
pubmed: 21642779
Environ Health Perspect. 2016 May;124(5):594-600
pubmed: 26517380
Diabet Med. 2000 Apr;17(4):299-307
pubmed: 10821297
J Intern Med. 2012 Dec;272(6):601-10
pubmed: 22812670
Biomarkers. 2016 Jul;21(5):429-35
pubmed: 26983064
PLoS One. 2015 Mar 27;10(3):e0121240
pubmed: 25816093
Epidemiology. 2016 Jan;27(1):125-32
pubmed: 26426943
J Environ Pathol Toxicol Oncol. 2000;19(3):201-13
pubmed: 10983887
J Toxicol Environ Health A. 2002 Oct 25;65(20):1531-43
pubmed: 12396867
Curr Atheroscler Rep. 2013 Oct;15(10):356
pubmed: 23955722
Environ Res. 2016 Aug;149:157-163
pubmed: 27208466
Indian Heart J. 1992 May-Jun;44(3):177-80
pubmed: 1427952

Auteurs

Huiqi Li (H)

Occupational and Environmental Medicine, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, P.O. Box 414, 405 30, Gothenburg, Sweden. huiqi.li@amm.gu.se.

Björn Fagerberg (B)

Department of Molecular and Clinical Medicine, Wallenberg Laboratory for Cardiovascular and Metabolic Research, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden.

Gerd Sallsten (G)

Occupational and Environmental Medicine, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, P.O. Box 414, 405 30, Gothenburg, Sweden.

Yan Borné (Y)

Cardiovascular Epidemiology, Department of Clinical Sciences in Malmö, Lund University and Skåne University Hospital, Malmö, Sweden.

Bo Hedblad (B)

Cardiovascular Epidemiology, Department of Clinical Sciences in Malmö, Lund University and Skåne University Hospital, Malmö, Sweden.

Gunnar Engström (G)

Cardiovascular Epidemiology, Department of Clinical Sciences in Malmö, Lund University and Skåne University Hospital, Malmö, Sweden.

Lars Barregard (L)

Occupational and Environmental Medicine, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, P.O. Box 414, 405 30, Gothenburg, Sweden.

Eva M Andersson (EM)

Occupational and Environmental Medicine, Sahlgrenska University Hospital and Sahlgrenska Academy, University of Gothenburg, P.O. Box 414, 405 30, Gothenburg, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH